News
ERAS
16.01
+7.09%
1.06
Erasca (ERAS) Could Be 40% Below Fair Value On Lawsuit And Trial Risk
Simply Wall St · 2d ago
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS
PR Newswire · 3d ago
Verastem says KRAS G12D inhibitor VS-7375 shows early activity in Phase 1/2 TARGET-D 101 trial across solid tumors
PUBT · 4d ago
Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR Newswire · 4d ago
Erasca (ERAS) Is Down 5.3% After ERAS-0015 Lawsuits Raise Data, Safety And IP Concerns
Simply Wall St · 5d ago
Law Offices of Frank R. Cruz Encourages Erasca, Inc. (ERAS) Shareholders To Inquire About Securities Fraud Class Action
Barchart · 6d ago
Weekly Report: what happened at ERAS last week (0615-0619)?
Weekly Report · 6d ago
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
PR Newswire · 6d ago
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS
PR Newswire · 06/19 13:00
ERAS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Barchart · 06/18 13:30
Deadline Alert: Erasca, Inc. (ERAS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Barchart · 06/18 11:00
Deadline Approaching: Erasca, Inc. (ERAS) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Barchart · 06/17 12:43
INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead the Erasca Class Action Lawsuit
PR Newswire · 06/17 12:00
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Barchart · 06/16 22:27
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS
PR Newswire · 06/16 22:12
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
PR Newswire · 06/16 18:21
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
PR Newswire · 06/16 16:00
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm, Encourages Erasca, Inc. (ERAS) Shareholders to Inquire About Securities Fraud Class Action
Barchart · 06/16 13:10
ERAS Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against Erasca, Inc.
PR Newswire · 06/16 02:11
Erasca (ERAS) Stock Valuation Under Scrutiny After ERAS-0015 Legal And Data Concerns
Simply Wall St · 06/16 00:22
More
Webull provides a variety of real-time ERAS stock news. You can receive the latest news about Erasca, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.